131I-MIBG + etoposide + melphalan + carboplatin + autologous peripheral stem cell transplantation

This is a high-dose cancer therapy regimen combining a radiopharmaceutical (131I-MIBG) with multiple chemotherapy agents (etoposide, melphalan, and carboplatin) followed by autologous peripheral stem cell transplantation. The therapy involves: 1. **131I-MIBG**: A radiopharmaceutical agent that targets specific cells. 2. **Etoposide**: A chemotherapy drug that inhibits topoisomerase II. 3. **Melphalan**: A high-dose chemotherapy drug, an alkylating agent. 4. **Carboplatin**: A platinum-based chemotherapy drug that causes DNA cross-linking. 5. **Autologous Peripheral Stem Cell Transplantation**: A procedure where the patient's own stem cells are collected, preserved, and reinfused after the high-dose therapy. This combination serves as a conditioning regimen to kill cancer cells, followed by stem cell rescue to restore bone marrow function damaged by the intensive treatment. The stem cell transplantation process involves: - **Stem Cell Collection**: Mobilizing stem cells from bone marrow to the bloodstream using growth factors and collecting them via apheresis. - **Conditioning Regimen**: Administering the high-dose chemotherapy and 131I-MIBG. - **Stem Cell Reinfusion**: Thawing and reinfusing the collected stem cells. - **Recovery**: Allowing transplanted stem cells to engraft in the bone marrow and produce new blood cells, typically taking 2-3 weeks.

Other names

131I-MIBG + etoposide + melphalan + carboplatin + Autologous Peripheral Stem Cell Transplantation131I-MIBG + CEM + APBSCT